Cingulate_Logo_400x400_twitter.jpg
Cingulate Announces Closing of $4.0 Million Public Offering
September 13, 2023 16:15 ET | Cingulate Inc.
KANSAS CITY, Kan., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Announces Pricing of $4.0 Million Public Offering
September 11, 2023 09:22 ET | Cingulate Inc.
KANSAS CITY, Kan., Sept. 11, 2023 (GLOBE NEWSWIRE) --  Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary...
tiziana-logo.png
Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 08, 2023 07:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
yield10.png
Yield10 Bioscience to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 07, 2023 08:31 ET | Yield10 Bioscience, Inc.
WOBURN, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that management will...
MustangBioLogo.jpg
Mustang Bio to Participate in Upcoming September 2023 Investor Conferences
September 07, 2023 08:15 ET | Mustang Bio, Inc.
WORCESTER, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
MNPR Triangle 2.JPG
Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 07:00 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
MustangBioLogo.jpg
Mustang Bio to Participate in Two August 2023 Investor Conferences
August 03, 2023 08:00 ET | Mustang Bio, Inc.
WORCESTER, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
ptx-logo .png
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
April 27, 2023 08:30 ET | Prelude Therapeutics, Inc.
WILMINGTON, Del., April 27, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will...
ihl_logo.png
Incannex to Participate in the Prestigious H.C. Wainwright 24th Annual Global Investment Conference
September 08, 2022 09:15 ET | Incannex Healthcare
MELBOURNE, Australia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a pharmaceutical company developing medicinal...
ptx-logo .png
Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences
September 06, 2022 08:00 ET | Prelude Therapeutics, Inc.
WILMINGTON, Del., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will be...